BioTheryX

Focus: BioTheryX is a Series C+ stage oncology-focused biotech company founded in 2009, specializing in small molecule therapeutics for cancer indications. Based in San Diego, the company is in early-stage development with two Phase 1 programs in its pipeline.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Total Funding

$150M

Open Jobs

About BioTheryX

AI assessmentNot Hiring

No open roles listed right now. Follow BioTheryX to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BTX-1188

Advanced Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05144334A Study of BTX-1188 in Subjects With Advanced Malignancies

Phase 1

Help build intelligence for BioTheryX

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology focus positions you at the frontier of small molecule drug discovery in a high-impact therapeutic area
San Diego location offers access to a robust biotech ecosystem and networking opportunities
Series C+ funding stage suggests sufficient capital runway to execute near-term milestones

Watch Out For

Zero active job openings currently listed indicates limited near-term hiring or potential organizational constraint
Pre-revenue stage with only two Phase 1 programs creates significant execution risk and extended timeline to meaningful clinical validation
Missing financial, employee count, and funding amount data raises transparency concerns about company stability and growth trajectory

Generated by Claude from BioTheryX's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BTX-9341

Breast Cancer

PHASE_1

Clinical Trials (1)

NCT06515470Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2009

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline